Tiragolumab and Atezolizumab in SMARCB1 or SMARCA4 Deficient Tumors

Tiragolumab and Atezolizumab in SMARCB1 or SMARCA4 Deficient Tumors

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description
This study enrolls patients that have been diagnosed with SMARCB1 or SMARCB4 deficient cancer that has either come back (“relapsed”) or does not respond to therapy (“is refractory”) or have been newly diagnosed with a SMARCB1 or SMARCB4 deficient cancer that has no known standard treatment. This study involves taking study drugs called tiragolumab and atezolizumab. These drugs are a type of immunotherapy that try to make the immune system fight cancer. The purpose of the study is to learn more about the safety of tiragolumab in children and to see how well the combination of tiragolumab and atezolizumab works when given to children and adults with these types of tumors. This study has two parts. In Part A, participants will receive tiragolumab. In Part B, participants will receive both tiragolumab and atezolizumab. 

What to expect
As a participant in the research, you will:
  • Receive study drugs called tiragolumab and atezolizumab
  • Complete frequent clinic visits at CHOP
  • Have frequent blood tests
  • Have extra or leftover tissue collected if you have a biopsy as part of your regular cancer care

Related specialties

Related conditions
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.